4-AcO-MPT

4-AcO-MPT
Clinical data
Other names4-Acetoxy-MPT; 4-Acetoxy-N-methyl-N-propyltryptamine
Routes of
administration
Oral
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • [3-[2-[methyl(propyl)amino]ethyl]-1H-indol-4-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H22N2O2
Molar mass274.364 g·mol−1
3D model (JSmol)
  • CCCN(C)CCC1=CNC2=C1C(=CC=C2)OC(=O)C
  • InChI=1S/C16H22N2O2/c1-4-9-18(3)10-8-13-11-17-14-6-5-7-15(16(13)14)20-12(2)19/h5-7,11,17H,4,8-10H2,1-3H3
  • Key:CECCEKYTLKWWJJ-UHFFFAOYSA-N

4-AcO-MPT, also known as 4-acetoxy-N-methyl-N-propyltryptamine, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to 4-AcO-DMT (psilacetin).[1][2][3][4][5]

Use and effects

Interactions

Pharmacology

Pharmacodynamics

4-AcO-MPT is thought to act as a prodrug of 4-HO-MPT and hence is believed to act as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor.[3][4] The receptor interactions of 4-AcO-MPT have been studied.[6] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents,[4]

Chemistry

Analogues

Analogues of 4-AcO-MPT include methylpropyltryptamine (MPT), 4-HO-MPT (meprocin), 5-MeO-MPT, 4-AcO-DMT (psilacetin), 4-AcO-MET (metacetin), 4-AcO-MiPT (mipracetin), and 4-AcO-DPT (depracetin), among others.

History

4-AcO-MPT was first described in the scientific literature by at least 2017.[2] It was first encountered as a novel designer drug in 2018.[1]

Society and culture

Canada

4-AcO-MPT is not a controlled substance in Canada as of 2025.[7]

Sweden

4-AcO-MPT is a controlled substance in Sweden.[8]

See also

References

  1. ^ a b "4-AcO-MPT". АИПСИН (in Russian). Retrieved 11 October 2025.
  2. ^ a b Chapman S (31 December 2017). PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra (PDF) (Report). doi:10.16889/isomerdesign-5. Retrieved 11 October 2025.
  3. ^ a b Berardinelli D, Montanari E, Malaca S, Zaami S, Busardò FP, Huestis MA, et al. (2022). "4-Hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) in vitro human metabolism". Toxicologie Analytique et Clinique. 34 (3): S96. Bibcode:2022ToxAC..34Q..96B. doi:10.1016/j.toxac.2022.06.147.
  4. ^ a b c Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC 8033608. PMID 33860183.
  5. ^ Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC 10111620. PMID 37082754.
  6. ^ Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacol Transl Sci. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC 10111620. PMID 37082754.
  7. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  8. ^ "4-AcO-MPT". АИПСИН (in Russian). Retrieved 2 January 2026.